Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition

Checkpoint inhibitors have revolutionized cancer therapy and validated immunotherapy as an approach. Unfortunately, responses are seen in a minority of patients. Our objective is to use engineered adenoviruses designed to increase lymphocyte trafficking and cytokine production at the tumor, to asses...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Principais autores: Cervera-Carrascon, Victor, Quixabeira, Dafne C.A., Santos, Joao Manuel, Havunen, Riikka, Zafar, Sadia, Hemminki, Otto, Heiniö, Camilla, Munaro, Eleonora, Siurala, Mikko, Sorsa, Suvi, Mirtti, Tuomas, Järvinen, Petrus, Mildh, Markus, Nisen, Harry, Rannikko, Antti, Anttila, Marjukka, Kanerva, Anna, Hemminki, Akseli
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7458667/
https://ncbi.nlm.nih.gov/pubmed/32923123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1761229
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados